Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
2 hedge funds and large institutions have $11K invested in Lixte Biotechnology Warrants in 2021 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0.15% less ownership
Funds ownership: 0.33% → 0.18% (-0.15%)
56% less capital invested
Capital invested by funds: $25K → $11K (-$14K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$7.09K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$893 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $8K | -$7.09K | -18,062 | -50% |
|
|
2
UBS Group
Zurich,
Switzerland
| $3K | -$893 | -2,274 | -27% |
|
LIXTW Hedge Fund Activity: Q4 2021 in Review
2 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q4 2021, worth a combined $11K — down 56% from $25K a quarter earlier.
Fund positioning in LIXTW was balanced in Q4 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was Warberg Asset Management, cutting an estimated $7.09K.
- 2 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $11K of Lixte Biotechnology Warrants stock for Q4 2021, down 56% quarter-over-quarter.
- 0 funds opened new Lixte Biotechnology Warrants positions in Q4 2021 and 0 closed out.
- The largest Lixte Biotechnology Warrants seller in Q4 2021 was Warberg Asset Management, an estimated $7.09K sold.
Based on aggregated 13F filings for Q4 2021.